15 Countries with the Highest Rates of Lung Cancer

In This Article:

In this article, we take a look at the 15 countries with the highest rates of lung cancer. If you would like to skip our detailed analysis of the lung cancer therapeutics industry, you can directly go to the 5 Countries with the Highest Rates of Lung Cancer.

Lung cancer is the second most common type of cancer in the world. Statistics worldwide showcase that the prevalance of the disease has increased globally over the past few years. This escalation in the number of individuals with lung cancer has led to a growing demand for advanced technology to deal with the illness and its side effects. As a result of this trend, the lung cancer therapeutics market has been witnessing steady growth all around the globe. According to Precedence Research, the global lung cancer therapeutics market was valued at $28 billion in 2022 and is expected to be worth more than $59.61 billion by 2032. The predicted CAGR for the period 2023-2032 is currently 7.90%, meaning that the industry is only anticipated to do well. 

If we take a region-wise approach, North America currently dominates the market and is expected to do so throughout the forecast period. The two main reasons for this market size are the increased penetration of health insurance and a significantly developed healthcare infrastructure. Furthermore, many leading biopharmaceutical companies are also present in this region, contributing immensely to the growth of the North American lung cancer market. You can also check out the 14 Best Cancer Stocks To Buy Now in order to get more insight on this topic. 

Bristol-Myers Squibb Co (NYSE:BMY) is one of the leading companies when it comes to cancer research in the US. The company has conducted detailed research trials on how lung cancer can be dealt with during the earlier stages of the disease before it spreads. As recently as September 2023, Bristol-Myers Squibb Co (NYSE:BMY) announced favorable results pertaining to a therapy method they were testing for non-small cell lung cancer. NSCLC is currently one of the most common types of lung cancer, and it can represent up to 84% of all diagnoses. Bristol-Myers Squibb Co (NYSE:BMY) has also been carrying out many other cancer-related trials side by side, some of which have received approval from the EU. 

Some of the latest research on lung cancer has shown that low-dose CT scans can help screen for lung cancer in those who smoke heavily. This is particularly helpful because lung cancer is more likely to be treated successfully if caught at earlier stages. Furthermore, the CDC reports that 80% to 90% of lung cancer-related deaths in the US are linked to tobacco smoking, making this the leading cause of the disease in the country. The issue's prevalence can be estimated from the fact that the size of the US tobacco industry, as estimated by Grand View Research, is $75.9 billion as of 2021, with the country being the world’s 9th largest tobacco exporter. So not only is tobacco production a national issue, but the industry has also expanded its operations beyond borders. You can check out the 12 Countries that Export the Most Tobacco to see the world’s leading contributors in the tobacco export industry.